FROM THE LIVER MEETING 2014A combined formula of ABT-450 with ritonavir, ombitasvir, and dasabuvir, given with ribavirin, yielded high rates of sustained viral response at 12 weeks among...
Viral suppression of hepatitis C virus–infected patients improved neural health as measured by magnetic resonance spectroscopy, according to findings from a new study.
Treatment led to an increase...
Sofosbuvir plus GS-5816 yielded high SVR rates in genotype 3 HCV patientsvitalsKey clinical point: Sofosbuvir plus GS-5816 was well tolerated and achieved high SVR rates among...
BOSTON - A hepatitis C treatment regimen of sofosbuvir and ledipasvir without ribavirin is associated with significant improvement in patient-reported outcomes, new research suggests.<br...
BOSTON – The graying of America will add at least 1 million more patients with chronic hepatitis C virus infection into the Medicare system between 2010 and 2024.
“If all of these patients were...
SAN FRANCISCO– A large retrospective study identified risk factors for anastomotic leak within 30 days of colectomy.
The analysis of data on 13,684 patients looked at a multicenter cohort, compared...
VIENNA – U.S. deaths from Clostridium difficile infection jumped roughly sevenfold from 1999 to 2008, but in the ensuing years (2009-2012), remained stable at about the level first reached in...
The Food and Drug Administration has approved the use of sofosbuvir in combination with simeprevir for treatment of patients with chronic hepatitis C virus. It is a ribavirin- and interferon-free...
Colorectal cancer rates have declined in both men and women since 1975, particularly in those over age 75 years, but there has also been a significant increase in the incidence among those aged 20-34...
Patients with chronic hepatitis C genotype 1 infection who relapse after sofosbuvir plus ribavirin may be successfully retreated with sofosbuvir plus ledipasvir, a new study demonstrated.
During the...
